Designed by: Astrid Többer Group: iGEM19_Bielefeld-CeBiTec (2019-10-15)
This part includes the genes II, X, V, VII, IX and VIII from the M13K07 helperphage.
Sequence and Features
Sequence was validated by Sanger sequencing. </html> Sequence and Features
- 10COMPATIBLE WITH RFC
- 12COMPATIBLE WITH RFC
- 21COMPATIBLE WITH RFC
- 23COMPATIBLE WITH RFC
- 25COMPATIBLE WITH RFC
- 1000COMPATIBLE WITH RFC
Assembly of Plasmids
We obtained the parts of gene II-VIII, gene III-IV, truncated gene III, terminator, and mCherry-VIII gene through PCR with customized primers. After proving the accuracy of the PCR product, we assembled the parts together through gibson assembly and transformed the assembled parts in E. coli DH5 alpha. After conducting growth experiments, we isolated the proteins and took them for a series of analysis to prove the existence of the parts in the assembled system.
The PCR yielded a product only on the supernatant of the culture containing E. coli transformed with the Assembly Plasmid and the Application Plasmid. In the culture of E. coli only with the Application Plasmid no PCR product is visible. This demonstrates, that E. coli with both plasmids produces our Troygenics and sets them free in the supernatant. So, their DNA is also detectable in the media. The missing PCR product in the sample from the culture with only the Troygenics DNA shows that this plasmid alone is, as expected, not sufficient to produce the Troygenics. Furthermore, this results shows, that occurrence of the PCR target inside E. coli cells does not interfere in this assay and produce false positive results. Therefore, this assay is an easy detection of Tryogenics production, assembly and export by our two-plasmid system.
After we redid the Troygenic purification with the expanded protocol from NEB, we did the ddPCR again.
This time there was even less E. coli DNA in the sample than before. The application plasmid is 4.1- and 21.4-times more common than the assembly plasmid or genomic E. coli DNA respectively. This experiment demonstrates, that the new protocol resulted in Troygenics with a higher purity. Additionally, the new protocol yielded a higher amount of purified Troygenic DNA.